In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line

Basit Öğe Kaydı
dc.contributor.authorTerzi, Hatice
dc.contributor.authorAltun, Ahmet
dc.contributor.authorSencan, Mehmet
dc.date.accessioned2024-10-26T18:04:15Z
dc.date.available2024-10-26T18:04:15Z
dc.date.issued2019
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground & objectives: Statins are one of the most widely used drugs and have antilipidemic effects as well as antioxidant, anti-inflammatory, anti-angiogenic and anti-tumorigenic effects. It has been shown that the synergistic combinations of statins which can provide better clinical benefit in the treatment of cancer and if administered with other anticancer agents, may be an alternative treatment modality. The aim of this study was to assess the efficacy of administrating statin in multiple myeloma (MM) cell line on cell proliferation. Methods: U266 myeloma cells were cultured in 25 or 75 cm[2] flasks by using cell culture medium mixtures obtained with the supplementation of 10 per cent foetal bovine serum and one per cent of penicillin-streptomycin into RPMI 1640 medium. When the cells reached confluence (reached to the density of 70%), they were reproduced by passaging. Cytotoxicity was evaluated by using the XTT test. Results: Statins (atorvastatin and simvastatin), were administered to the U266 myeloma cell line at 100, 50, 25, 12.5, 6.25 and 3.12 mu M concentrations. Inhibitor concentration 50 (IC50) values calculated for atorvastatin and simvastatin were determined as 94 and 38 mu M, respectively. While 100, 50, 25, 12.5, 6.25 and 3.12 mu M concentrations were used for bortezomib, the IC50value calculated for this agent was 18.2 nM. When six concentrations of bortezomib used in the study were combined with 12.5 mu M inactive concentrations of statins that did not cause inhibition in cell proliferation, both atorvastatin and simvastatin increased the effect of bortezomib at all the concentrations used, and simvastatin showed a stronger efficacy than atorvastatin. Interpretation & conclusions: Our in vitro results indicated that atorvastatin and simvastatin when used along with the conventional treatment in myeloma patients, may improve the effectiveness of the standard therapy and prevent the bortezomib-induced cytotoxic and neurotoxic side effects when used at a low dose. Further studies need to be done in MM patints to confirm these findings.
dc.identifier.doi10.4103/ijmr.IJMR_672_18
dc.identifier.endpage634
dc.identifier.issn0971-5916
dc.identifier.issue6
dc.identifier.pmid32048627
dc.identifier.scopus2-s2.0-85079337222
dc.identifier.scopusqualityQ2
dc.identifier.startpage630
dc.identifier.urihttps://doi.org/10.4103/ijmr.IJMR_672_18
dc.identifier.urihttps://hdl.handle.net/20.500.12418/28836
dc.identifier.volume150
dc.identifier.wosWOS:000533429900015
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofIndian Journal of Medical Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleIn vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu